Advancing Disease-Modifying Pulmonary Fibrosis Drugs
2023 Attending Companies
With Nintedanib and Pirfenidone set to lose their patents in the next 3-6 years, Pliant Therapeutics moving into phase 2b, Vicore and Galecto’s phase 2 studies expected to read out, and Bristol Myers Squibb’s and Boehringer Ingelheim’s clinical trials both well under way…the race is on to advance the next generation of idiopathic pulmonary fibrosis drugs and beat the benchmark set by the standard of care. 2023 has already been a turbulent year...
We’re at the precipice of hailing disease-modifying IPF drugs to patients with the increasing understanding of lung pathobiology and cell cross talk using multi-omic approaches expanding the horizons of therapeutic targets to slow, halt, reverse and regenerate progressively fibrosing lung tissue. Imaging and AI are being harnessed more than ever to show therapeutic efficacy beyond lung function and clinical trials are being designed to be more effective and swifter.
The 7th IPF Summit was the undisputed, comprehensive, end-to-end, 3-day conference for you and your team to grasp the latest readouts and take new insights back to your therapeutic development. Don’t miss this opportunity next year to discuss the latest unpublished data and network with 150+ movers and shakers in the pulmonary fibrosis field.
Fresh Faces & Returning KOLs
We're pleased to have welcomed 31+ new speakers for this year alongside 19 returning organizations to the agenda to give you the latest updates directly from senior decision makers in the field.
3-Track Seminar Day
Attendees had the opportunity to take advantage of our new tracked seminar day, which allowed them to get in-depth content suitable for their therapeutic stage. They chose between:
- Emerging Biology Seminar Day
- Translational Seminar Day
- Clinical Seminar Day
New Ambassador Evening!
Attendees had the opportunity to connect with their peers the evening before the main conference in a relaxed atmosphere and listened to a Fireside Chat on the future of therapeutic development from pulmonary fibrosis leaders
Who Did You Meet?
Take a look at who was at this year’s summit to understand whether the IPF Summit 2024 is for you!
- Director, Scientific Precision Medicine
- Vice President, Strategic Partners
- Chief Executive Officer
- Chief Scientific Officer
- Chief Medical Officer
- Medical Director, Clinical Development
- Consultant, Research
- Head of Bioinformatics & Translational Sciences
- Executive Vice President, Business Development
- Senior Scientist, Immunology
- Medical Director, Respiratory
- Senior Director, Clinical Development
- Director, Clinical Trial & Clinical Operation
- Director, Scientific Translational Development
- Research Scientist
- Senior Director, Respiratory
- Scientist Platform Biology
- Head of Therapeutics Discovery
- Executive Director, Medical Affairs
- Senior Director, Toxicology & Nonclinical Development
- Director, Biology
- Research Scientist, Bioinformatics
- Senior Research Scientist, Biomarkers
- Senior Associate Scientist, Fibrosis
- Director & Head of Area, Respiratory
- Global Program Clinical Head
- Preclinical Director
- Vice President, Research & Development
- Director, In Vivo Pharmacology
Exclusive Interview with Deciduous Therapeutics
We caught up with Robin Mansukhani, Chief Executive Officer and Scott Armstrong, VP of Research at Deciduous Therapeutics ahead of the 7th IPF Summit 2023.
Don't miss Deciduous Therapeutics' session on the agenda:
Resolving Pulmonary Fibrosis via Immune Mediated Senolysis
Robin Mansukhani, Chief Executive Officer, Deciduous Therapeutics
See the full agenda here.
Your 2023 World Class Speaker Faculty Included:
Executive Director – Medical Early Clinical Development, Respiratory & Immunology
Executive Medical Director, Early Clinical Development & Experimental Sciences
Chief of Pulmonary & Critical Care
Weill Cornell Medical College
"The IPF Summit, time and again, proves its value to investigators, academicians, and drug developers alike for the insights it generates and the networking it affords”
Senior Lead – Clinical Program & Interstitial Lung Disease , Boehringer Ingelheim
"A great opportunity to discuss advances and opportunities in clinical and translational science in the interest of advancing care for patients with IPF”
Head of Biomarker Discovery , AstraZeneca
"Being part of the conversation for developing novel IPF therapies”
Chief Medical Officer ,Pliant Therapeutics
"Connecting with colleagues and learning about new science and clinical development related to lung fibrosis”
Executive Medical Director, Early Clinical Development & Experimental Sciences, , Regeneron Pharmaceuticals
"Provide valuable insight into biomarker development and implementation in patients with IPF”
Clinical Associate Professor , University of Michigan
"Opportunity to learn from diverse attendees ranging from basic scientist, academic physicians, seasoned clinical trialists, and industry experts. A comprehensive range of topics will be covered that span exciting advances in knowledge on the pathogenesis of IPF, novel in vitro and in vivo models of pulmonary fibrosis, novel endpoints to accelerate development of clinical trials, and optimal recruitment strategies to deliver clinical studies”
Executive Director – Early Clinical Development, Respiratory & Immunology , AstraZeneca
"I’ve thoroughly enjoyed attending the IPF Summit - a conference for innovators – it’s a premier event for therapeutic advancements in a fatal lung disease”
Chief Medical Officer , Vicore Pharma